Mana.bio is an AI based drug delivery startup, focusing on gene therapy including DNA and RNA-based therapeutics, and vaccines.
Mana.bio has raised $19.5M in total funding. The most recent round was Seed. The last funding was announced in October 2023.
Mana.bio's investors include Andreessen Horowitz, NFX, LionBird, Technion - Israel Institute of Technology, Base4 Capital.
Mana.bio is headquartered in San Francisco, United States.
Mana.bio is an AI based drug delivery startup, focusing on gene therapy including DNA and RNA-based therapeutics, and vaccines.
Mana.bio is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Mana.bio — Funding & Investors." VCBacked, October 10, 2023, https://www.vcbacked.co/company/manabio. Accessed August 1, 2026.
VCBacked. (2023). Mana.bio — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/manabio
{{cite web |title=Mana.bio — Funding & Investors |url=https://www.vcbacked.co/company/manabio |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated